白血病·淋巴瘤
白血病·淋巴瘤
백혈병·림파류
JOURNAL OF LEUKEMIA & LYMPHOMA
2012年
8期
468-471
,共4页
刘宗晋%张巧花%侯淑玲%郭素堂%杨瑞红
劉宗晉%張巧花%侯淑玲%郭素堂%楊瑞紅
류종진%장교화%후숙령%곽소당%양서홍
光谱法,质量,基质辅助激光解吸电离%T淋巴细胞%淋巴瘤,非霍奇金
光譜法,質量,基質輔助激光解吸電離%T淋巴細胞%淋巴瘤,非霍奇金
광보법,질량,기질보조격광해흡전리%T림파세포%림파류,비곽기금
Spectrometry,mass,matrix-assisted laser desorption-ionization%T-lymphocytes%Lymphoma,non-Hodgkin's
目的 研究T细胞非霍奇金淋巴瘤(T-NHL)患者血清差异蛋白质质谱的表达及其临床价值.方法 应用蛋白芯片表面加强激光解吸电离-飞行时间质谱(SELDI-TOF-MS)技术wcx-2芯片检测36例T-NHL患者和30例弥漫大B细胞淋巴瘤(DLBCL)患者血清蛋白质质谱,用生物化学法测定T-NHL患者血清乳酸脱氢酶(LDH)水平,用酶联免疫吸附法(ELISA)测定β2-微球蛋白(β2-MG)水平.分析T-NHL患者与DLBCL患者间质谱检测差异表达的蛋白质,同时分析差异蛋白质丰度与疾病分期、LDH及β2-MG水平的相关性.结果 与DLBCL患者比较,在T-NHL患者血清中共检测出9个差异蛋白质,其相对分子质量分别为1142.67、1451.43、1472.49、1512.03、3194.22、3267.41、3933.86、4593.12、9182.24.这些差异蛋白质的表达水平在T-NHL不同分期间差异无统计学意义(均P＞0.05).4593.12和9182.24蛋白质质谱在T-NHL中高表达,在这两种蛋白质阳性组中,LDH表达水平分别为( 290.82±29.95)U/L、(283.94±100.94)U/L,明显高于阴性组的(169.22±55.42)U/L、(169.50±59.25)U/L(t=-3.199,P=0.004;t=-2.378,P=0.026),两组蛋白质的峰值与LDH的水平呈正相关(r=0.265,r=0.178,均P＜0.01);在这两种蛋白质阳性组与阴性组间[β2-MG表达水平差异无统计学意义(P＞0.05).其他7种蛋白质在T-NHL患者血清中低表达,LDH、β2-MG水平在这些蛋白质质谱中差异无统计学意义(均P＞ 0.05).结论 相对分子质量为4593.12和9182.24的蛋白质可能是鉴别T-NHL的特异血清学标志,它们可和LDH联合用于评估患者的肿瘤负荷,为临床治疗提供一定的指导.
目的 研究T細胞非霍奇金淋巴瘤(T-NHL)患者血清差異蛋白質質譜的錶達及其臨床價值.方法 應用蛋白芯片錶麵加彊激光解吸電離-飛行時間質譜(SELDI-TOF-MS)技術wcx-2芯片檢測36例T-NHL患者和30例瀰漫大B細胞淋巴瘤(DLBCL)患者血清蛋白質質譜,用生物化學法測定T-NHL患者血清乳痠脫氫酶(LDH)水平,用酶聯免疫吸附法(ELISA)測定β2-微毬蛋白(β2-MG)水平.分析T-NHL患者與DLBCL患者間質譜檢測差異錶達的蛋白質,同時分析差異蛋白質豐度與疾病分期、LDH及β2-MG水平的相關性.結果 與DLBCL患者比較,在T-NHL患者血清中共檢測齣9箇差異蛋白質,其相對分子質量分彆為1142.67、1451.43、1472.49、1512.03、3194.22、3267.41、3933.86、4593.12、9182.24.這些差異蛋白質的錶達水平在T-NHL不同分期間差異無統計學意義(均P＞0.05).4593.12和9182.24蛋白質質譜在T-NHL中高錶達,在這兩種蛋白質暘性組中,LDH錶達水平分彆為( 290.82±29.95)U/L、(283.94±100.94)U/L,明顯高于陰性組的(169.22±55.42)U/L、(169.50±59.25)U/L(t=-3.199,P=0.004;t=-2.378,P=0.026),兩組蛋白質的峰值與LDH的水平呈正相關(r=0.265,r=0.178,均P＜0.01);在這兩種蛋白質暘性組與陰性組間[β2-MG錶達水平差異無統計學意義(P＞0.05).其他7種蛋白質在T-NHL患者血清中低錶達,LDH、β2-MG水平在這些蛋白質質譜中差異無統計學意義(均P＞ 0.05).結論 相對分子質量為4593.12和9182.24的蛋白質可能是鑒彆T-NHL的特異血清學標誌,它們可和LDH聯閤用于評估患者的腫瘤負荷,為臨床治療提供一定的指導.
목적 연구T세포비곽기금림파류(T-NHL)환자혈청차이단백질질보적표체급기림상개치.방법 응용단백심편표면가강격광해흡전리-비행시간질보(SELDI-TOF-MS)기술wcx-2심편검측36례T-NHL환자화30례미만대B세포림파류(DLBCL)환자혈청단백질질보,용생물화학법측정T-NHL환자혈청유산탈경매(LDH)수평,용매련면역흡부법(ELISA)측정β2-미구단백(β2-MG)수평.분석T-NHL환자여DLBCL환자간질보검측차이표체적단백질,동시분석차이단백질봉도여질병분기、LDH급β2-MG수평적상관성.결과 여DLBCL환자비교,재T-NHL환자혈청중공검측출9개차이단백질,기상대분자질량분별위1142.67、1451.43、1472.49、1512.03、3194.22、3267.41、3933.86、4593.12、9182.24.저사차이단백질적표체수평재T-NHL불동분기간차이무통계학의의(균P＞0.05).4593.12화9182.24단백질질보재T-NHL중고표체,재저량충단백질양성조중,LDH표체수평분별위( 290.82±29.95)U/L、(283.94±100.94)U/L,명현고우음성조적(169.22±55.42)U/L、(169.50±59.25)U/L(t=-3.199,P=0.004;t=-2.378,P=0.026),량조단백질적봉치여LDH적수평정정상관(r=0.265,r=0.178,균P＜0.01);재저량충단백질양성조여음성조간[β2-MG표체수평차이무통계학의의(P＞0.05).기타7충단백질재T-NHL환자혈청중저표체,LDH、β2-MG수평재저사단백질질보중차이무통계학의의(균P＞ 0.05).결론 상대분자질량위4593.12화9182.24적단백질가능시감별T-NHL적특이혈청학표지,타문가화LDH연합용우평고환자적종류부하,위림상치료제공일정적지도.
Objective To find differential expression proteins in patients with T cell non-Hodgkin’ s lymphoma (T-NHL) by using surface-enhanced laser desorption and ionization time-of-flight mass spectrometry (SELDI-TOF-MS) technique and study their related clinical application value and prospect.Methods Serum protein of 36 T-NHL patients and 30 DLBCL patients were detected by the SELD1-TOF-MS technique and weak cation exchange (wcx-2) chip.Lactate dehydrogenase (LDH) was detected by biochemistry method.Beta2-microglobulin (β2-MG) was detected by enzyme-linked immunesorbent assay (ELISA).The significant different protein spectrometry were analyzed between DLBCL patients and T-NHL patients.The correlation analysis with protein spectrometry,disease staging,LDH and β2-MG were analyzed with Spearman.Results Nine potential candidate proteins,including the peak intensity of M/Z 1142.67,1451.43,1472.49,1512.03,3194.22,3267.41,3933.86,4593.12 and 9182.24,were identified in T-NHL patients.The 9 protein markers had no contact with disease staging of T-NHL (P ＞ 0.05).The protein markers of 4593.12 and 9182.24 were high level in T-NHL patients.LDH in these two protein markers’ positive group [(290.82±29.95) U/L,(283.94±100.94) U/L] was higher than that in negative group [(169.22±55.42) U/L,(169.50±59.25) U/L](t =-3.199,P =0.004; t =-2.378,P =0.026),and LDH was positive correlation with these two protein spectrometry (r =0.265,r =0.178,P ＜ 0.01).There was no statistically significant difference ofβ2-MG between these two protein markers’ positive group and negative group (P ＞ 0.05).The other 7 protein markers were low level in T-NHL patients,and there was no statistically significant difference of LDH and β2-MG in these 7 protein markers (P ＞ 0.05).Conclusion The protein marker of 4593.12 and 9182.24 may be the specific serological markers to identify T-NHL.The combination of these two protein markers and LDH may assess the tumor load,and provide guiding value for clinical treatment.
